11:32pm Thursday 21 June 2018

Study identifies cellular ‘death code’

Stanford scientists and their collaborators have discovered a molecule that initiates the final, crucial step in a type of cell death.

Dying cells generally have two options: go quietly, or go out with a bang.

The latter, while more conspicuous, is also mechanistically more mysterious. Now, scientists at the Stanford University School of Medicine have pinpointed what they believe is the molecular “code” that unleashes this more violent variety of cell death.

This particular version of cell suicide is called necroptosis, and it typically occurs as a result of some sort of infection or pathogenic invader. “Necroptosis is sort of like the cell’s version of ‘taking one for the team,’” said Jan Carette, PhD, assistant professor of microbiology and immunology. “As the cell dies, it releases its contents, including a damage signal that lets other cells know there’s a problem.”

Seen in this light, necroptosis seems almost altruistic, but the process is also a key contributor to autoimmune diseases; it’s even been implicated in the spread of cancer.

In a new study, Carette and his collaborators discovered the final step of necroptosis, the linchpin upon which the entire process depends. They call it “the death code.”

Their work, which was published online June 7 in Molecular Cell, not only clears up what happens during this type of cell death, but also opens the door to potential new treatments for diseases in which necroptosis plays a key role, such as inflammatory bowel disease and multiple sclerosis. Carette is the senior author, and postdoctoral scholar Cole Dovey, PhD, is the lead author.

Initiating detonation

When a cell’s health is threatened by an invader, such as a virus, a cascade of molecular switches and triggers readies the cell for death by necroptosis. Until recently, scientists thought they had traced the pathway down to the last step. But it turns out that the entire chain is rendered futile without one special molecule, called inositol hexakisphosphate, or IP6, which is part of a larger collection of molecules known as inositol phosphates. Carette likens IP6 to an access code; only in this case, when the code is punched in, it’s not a safe or a cellphone that’s unlocked: It’s cell death. Specifically, a protein called MLKL, which Carette has nicknamed “the executioner protein,” is unlocked.

Genetic screens are a lot of fun because you never know what you’re going to get.

“This was a big surprise. We didn’t know that the killer protein required a code, and now we find that it does,” Dovey said. “It’s held in check by a code, and it’s released by a code. So only when the code is correct does the killer activate, puncturing holes in the cell’s membrane as it prepares to burst the cell open.”

MLKL resides inside the cell, which may seem like an error on evolution’s part; why plant an explosive in life’s inner sanctum? But MLKL is tightly regulated, and it requires multiple green lights before it’s cleared to pulverize. Even if all other proteins and signaling molecules prepare MLKL for destruction, IP6 has the final say. If IP6 doesn’t bind, MLKL remains harmless, like a cotton ball floating inside the cell.

When it’s not killing cells, MLKL exists as multiple units, separate from one another. But when IP6 binds to one of these units, the protein gathers itself up into one functional complex. Only then, as a whole, is MLKL a full-fledged killer. It’s like a grenade split into its component parts. None of them are functional on their own. But put back together, the tiny bomb is ready to inflict damage.

“We’ve come to realize that, after the cell explodes, there are these ‘alarm’ molecules that alert the immune system,” Dovey said. “When the cell releases its contents, other cells pick up on these cautionary molecules and can either shore up defenses or prepare for necroptosis themselves.”

Screening for the Grim Reaper

In their quest to understand exactly how necroptosis occurs, Carette and Dovey performed an unbiased genetic screen, in which they scoured the entire genome for genes that seemed to be particularly critical toward the end of the pathway, where they knew MLKL took action. Before the IP6 finding, it was known that an intricate pathway impinged on MLKL. But only through this special genetic screen, in which they systematically tested the function of every gene at this end stage, were they able to see that IP6 was the key to necroptosis.

“Genetic screens are a lot of fun because you never know what you’re going to get,” Carette said. “We feel quite excited that we’ve been able to pinpoint IP6.”

Their screen revealed that IP6 binds with especially high specificity. Other similar versions of inositol phosphate, such as IP3, didn’t pass muster, and when bound to MLKL had no effect. This gave Carette an interesting idea. For conditions like irritable bowel disease, in which erroneous necroptosis contributes to the severity of the disease, it would be desirable to disable IP6 from binding under those conditions. Perhaps blocking the binding site, or tricking MLKL into binding to one of the other versions of inositol phosphate, could do the trick. Either way, Carette and his collaborators are now digging further into the structure of IP6 bound to MLKL to better understand exactly how the killer is unleashed.

“In terms of drug discovery, inositol phosphates have been somewhat ignored, so we’re really excited to be able to look into these small molecules for potential therapeutic reasons,” Carette said .

Other Stanford co-authors on the study are graduate student Jonathan Diep; postdoctoral scholar Jennifer Yinuo Cao, PhD; and assistant professor of biology Scott Dixon, PhD.

Carette is a member of Stanford Bio-XStanford ChEM-H and the Stanford Child Health Research Institute.

Researchers at Vanderbilt University, St. Jude Children’s Research Hospital, the University of Texas, Princeton University, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, GlaxoSmithKline and Emory University also contributed to the work.

The study was supported by the National Institutes of Health (grants T32AI007328, DP2AI104557, 5T32GM007347, R01AI020211 and R01GM124404), the David and Lucile Packard FoundationSt. Jude Children’s Research Hospital and the American Lebanese Syrian Associated Charities, the fundraising organization for St. Jude.

Stanford’s Department of Microbiology and Immunology also supported the work.


Stanford Medicine integrates research, medical education and health care at its three institutions – Stanford University School of MedicineStanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children’s Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.

 

 

 

 


Share on:
or:

MORE FROM Immune System

Health news